当前位置: 首页 >> 检索结果
361. Cost-effectiveness of and satisfaction with a Helicobacter pylori "test and treat" strategy compared with prompt endoscopy in young Asians with dyspepsia.
To compare a Helicobacter pylori "test and treat" strategy with prompt endoscopy in young Asians with dyspepsia.
362. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines.
作者: T Aebischer.;D Bumann.;H J Epple.;W Metzger.;T Schneider.;G Cherepnev.;A K Walduck.;D Kunkel.;V Moos.;C Loddenkemper.;I Jiadze.;M Panasyuk.;M Stolte.;D Y Graham.;M Zeitz.;T F Meyer.
来源: Gut. 2008年57卷8期1065-72页
Helicobacter pylori remains a global health hazard, and vaccination would be ideal for its control. Natural infection appears not to induce protective immunity. Thus, the feasibility of a vaccine for humans is doubtful.
363. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions.
作者: F J C van den Broek.;P Fockens.;S van Eeden.;J B Reitsma.;J C H Hardwick.;P C F Stokkers.;E Dekker.
来源: Gut. 2008年57卷8期1083-9页
Endoscopic tri-modal imaging (ETMI) incorporates white light endoscopy (WLE), autofluorescence imaging (AFI) and narrow-band imaging (NBI).
364. Adenosine modulates oesophageal sensorimotor function in humans.
Adenosine mediates somatic and visceral pain, but its effects on gut visceral nociception are unknown. The aim of the present study was to test the hypothesis that adenosine alters oesophageal sensorimotor function.
365. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
作者: M A Kamm.;G R Lichtenstein.;W J Sandborn.;S Schreiber.;K Lees.;K Barrett.;R Joseph.
来源: Gut. 2008年57卷7期893-902页
Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once-daily, high-strength (1.2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis.
366. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis.
Risk factors for mortality and re-bleeding following acute variceal haemorrhage (AVH) are incompletely understood. The aim of this study was to determine risk factors for 6-week mortality, and re-bleeding within 5 days in patients with cirrhosis and AVH.
367. Confocal chromoscopic endomicroscopy is superior to chromoscopy alone for the detection and characterisation of intraepithelial neoplasia in chronic ulcerative colitis.
The diagnosis of intraepithelial neoplasia is pivotal for ongoing clinical management decisions in ulcerative colitis. Previous studies have compared the diagnostic yield of endomicroscopy with conventional "white light" endoscopy and hence the overall objective increase of endomicroscopy targeted biopsies as compared to chromoscopy guided alone is not apparent.
368. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study.
作者: M R Kraus.;A Schäfer.;K Schöttker.;C Keicher.;B Weissbrich.;I Hofbauer.;M Scheurlen.
来源: Gut. 2008年57卷4期531-6页
Interferon-induced depression represents a major complication in antiviral treatment of chronic hepatitis C virus (HCV) infection.
369. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials.
Functional dyspepsia (FD) is a common disorder but there is currently little efficacious drug therapy. Itopride, a prokinetic approved in several countries, showed promising efficacy in FD in a phase IIb trial. The aim of this study was to test the efficacy and safety of this drug in FD.
370. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
作者: C-H Liu.;C-C Liang.;J-W Lin.;S-I Chen.;H-B Tsai.;C-S Chang.;P-H Hung.;J-H Kao.;C-J Liu.;M-Y Lai.;J-H Chen.;P-J Chen.;J-H Kao.;D-S Chen.
来源: Gut. 2008年57卷4期525-30页
Chronic hepatitis C virus (HCV) infection is prevalent in dialysis patients, and standard interferon monotherapy is the current standard of care for such patients.
371. Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B.
作者: H J Flink.;E H C J Buster.;I Merican.;F Nevens.;G Kitis.;J Cianciara.;R A de Vries.;B E Hansen.;S W Schalm.;H L A Janssen.
来源: Gut. 2007年56卷10期1485-6页 372. Sensitivity and specificity of bispectral index for classification of overt hepatic encephalopathy: a multicentre, observer blinded, validation study.
作者: A A Dahaba.;H C Worm.;S M Zhu.;F P Bao.;A Salah.;S Zakaria.;H Bornemann.;V Stadlbauer.;P H Rehak.;H Metzler.;R E Stauber.
来源: Gut. 2008年57卷1期77-83页
The severity of hepatic encephalopathy is currently graded clinically using West Haven criteria and psychometric tests.
373. A prospective randomised study on narrow-band imaging versus conventional colonoscopy for adenoma detection: does narrow-band imaging induce a learning effect?
作者: A Adler.;H Pohl.;I S Papanikolaou.;H Abou-Rebyeh.;G Schachschal.;W Veltzke-Schlieker.;A C Khalifa.;E Setka.;M Koch.;B Wiedenmann.;T Rösch.
来源: Gut. 2008年57卷1期59-64页
Colonoscopy is an established method of colorectal cancer screening, but has an adenoma miss rate of 10-20%. Detection rates are expected to improve with optimised visualisation methods. This prospective randomised study evaluated narrow-band imaging (NBI), a new technique that may enhance image contrast in colon adenoma detection.
374. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
作者: Masao Omata.;Haruhiko Yoshida.;Joji Toyota.;Eiichi Tomita.;Shuhei Nishiguchi.;Norio Hayashi.;Shiro Iino.;Isao Makino.;Kiwamu Okita.;Gotaro Toda.;Kyuichi Tanikawa.;Hiromitsu Kumada.; .
来源: Gut. 2007年56卷12期1747-53页
Combined pegylated interferon and ribavirin has improved chronic hepatitis C (CH-C) therapy; however, sustained virological response is achieved in only about half of the patients with a 1b genotype infection. We assessed oral ursodeoxycholic acid (UDCA) on serum biomarkers as a possible treatment for interferon non-responders.
376. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome.
作者: L A Houghton.;C Fell.;P J Whorwell.;I Jones.;D P Sudworth.;J D Gale.
来源: Gut. 2007年56卷9期1218-25页
Visceral hypersensitivity is an important pathophysiological factor in irritable bowel syndrome (IBS). Pre-clinical studies suggest that the alpha(2)delta ligand pregabalin reduces both visceral allodynia and hyperalgesia, but is inactive on basal sensitivity.
379. Randomised, double blind, placebo controlled trial of intravenous antioxidant (n-acetylcysteine, selenium, vitamin C) therapy in severe acute pancreatitis.
作者: Ajith K Siriwardena.;James M Mason.;Srinivasan Balachandra.;Anil Bagul.;Simon Galloway.;Laura Formela.;Jonathan G Hardman.;Saurabh Jamdar.
来源: Gut. 2007年56卷10期1439-44页
Based on equivocal clinical data, intravenous antioxidant therapy has been used for the treatment of severe acute pancreatitis. To date there is no randomised comparison of this therapy in severe acute pancreatitis.
|